share_log

Keybanc Maintains Overweight on Conmed, Raises Price Target to $141

Benzinga ·  Jul 27, 2023 04:34

Keybanc analyst Matthew Mishan maintains Conmed (NYSE:CNMD) with a Overweight and raises the price target from $131 to $141.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment